# Wellington Global Health Care Equity Fund USD S Accumulating Unhedged

## MORNINGSTAR™ RATING: ★★★★★

### **FUND DETAILS**

Fund Inception: November 2000

Share Class Inception: October 2003

Fund Assets: USD 2.3 billion

NAV\*: USD 59.05

\*Please note the fund has a partial swing pricing mechanism in place.

#### **KEY INFORMATION**

Domicile/Type: Ireland/UCITS

Dealing Frequency: Daily

**Country Registration:** Austria, Denmark, Germany, Ireland, Netherlands, Singapore\*, South Korea, Spain, Switzerland, United Kingdom

**ISIN:** IE00B0590K11

Bloomberg: WGHCEPA ID

Lipper: 65021878

WKN: A0Q3U2

\*Restricted scheme

#### FUND CHARACTERISTICS

Asset-Weighted Market Capitalisation:	USD 47.8 billion
Beta (3 Yr):	1.19
Tracking Risk (3 Yr, annualised):	7.4%
Turnover:	31.7%

## FEES AND PRICING\*

Minimum Investment: USD 5 million

Management Fee: 1.25%

#### Ongoing Charges Figure: 1.32%

\*The Ongoing Charges Figure represents all annual expenses and additional charges taken from the fund. A more detailed description of the charges that apply to the Fund is set out in the section "Charges and Expenses" in the Prospectus.

For more information, please visit www.wellingtonfunds.com

## SUMMARY OF INVESTMENT OBJECTIVE


The Wellington Global Health Care Equity Fund seeks long-term total returns. The Investment Manager will actively manage the Fund, seeking to achieve the objective by investing in the equity securities of health care companies worldwide. The Fund takes a long term value approach and seeks to invest in fundamentally sound companies. Although the Fund is not constructed relative to a benchmark, the MSCI World Health Care index will serve as a reference benchmark.

## FUND PERFORMANCE (%)

## TOTAL RETURNS NET OF FEES AND EXPENSES

	YTD	1 MO	3 MOS	1 YR	3 YRS	5 YRS	10 YRS	SINCE INCEPTION
USD S Acc Unhdg	13.3	3.9	2.9	7.0	13.0	9.6	17.7	12.2
MSCI World Health Care NET	7.2	2.0	-1.4	9.0	10.5	7.5	14.5	9.0

#### CALENDAR YEAR RETURNS



#### DISCRETE ANNUAL PERFORMANCE

	FEB '18 – '19	FEB '17 – '18	FEB '16 – '17	FEB '15 – '16	FEB '14 – '15
USD S Acc Unhdg	7.0	10.5	21.9	-10.5	22.8
MSCI World Health Care NET	9.0	11.8	10.7	-9.3	17.3

#### Past results are not necessarily indicative of future results and an investment can lose value.

The inception date of the USD S Acc Unhdg share class is 31 October 2003. Fund returns shown are net of USD S Acc Unhdg class fees and expenses. Periods greater than one year are annualised. Fund returns are shown net of actual (but not necessarily maximum) withholding tax but are not otherwise adjusted for the effects of taxation and assume reinvestment of dividends and capital gains. The index returns shown are net of maximum withholding tax and assume reinvestment of dividends. | Please note the fund has a partial swing pricing mechanism in place. | Sources: Fund - Wellington Management. Index - MSCI.

#### **FUND MANAGERS**



Jean M Hynes, CFA 27 years of experience

# Ann 0 29 ye

Ann C Gallo 29 years of experience

Wellington Management Company LLP (WMC) is an independently owned investment adviser registered with the US Securities and Exchange Commission. WMC is also a commodity trading advisor (CTA) registered with the US Commodity Futures Trading Commission. In certain circumstances, WMC provides commodity trading advice to clients in reliance on exemptions from CTA registration. WMC, along with its affiliates (collectively, Wellington Management), provides investment management and investment advisory services to institutions around the world. Past results are not necessarily indicative of future results and in investment can lose value. | This material and its contents may not be reproduced or distributed, in whole or in part, without the express written consent of Wellington Management. This document is intended for marketing purposes only. It is not an offer or a solicitation by anyone, to subscribe for shares/units of any Wellington Management Fund (the Fund). Nothing in this document should be interpreted as advice, nor is it a recommendation to buy or sell shares/units. The Fund only accepts professional clients or investment through financial advisers. Any views expressed are those of the author at the time of writing and are subject to change without notice. Except where registration of the Fund offering documents, and latest annual report (and semi-annual report) before investing. In Switzerland, these can be obtained from the local Representative and Paying Agent – BNP Paribas Securities Services, Selnaustrasse 16, 8002 Zurich, Switzerland. The Prospectus is available in English, French and Swiss French (for share/unit classes registered in Switzerland, and (3) is not warranted to be accurate, complete or timely. Neither Morningstar, (2) may not be copied or distributed, and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damage so losses arising from any use of this information. The Overall Morningstar, (2) may not be copi

# WHAT ARE THE RISKS?

CAPITAL: Investment markets are subject to economic, regulatory, market sentiment and political risks. All investors should consider the risks that may impact their capital, before investing. The value of your investment may become worth more or less than at the time of the original investment. The Fund may experience a high volatility from time to time.

EQUITIES: Investments may be volatile and will fluctuate according to market conditions and the performance of individual companies and that of the broader equity market.

MANAGER: Investment performance depends on the investment management team and their investment strategies. If the strategies do not perform as expected, if opportunities to implement them do not arise, or if the team does not implement its investment strategies successfully; then a fund may underperform or experience losses.

**CONCENTRATION:** Concentration of investments within securities, issuers, sectors, industries, or geographical regions may impact performance.

**CURRENCY:** The value of the Fund may be affected by changes in currency exchange rates. Unhedged currency risk may subject the Fund to significant volatility.


SMALL AND MID-CAP COMPANY:Small and mid-cap companies' valuations may be more volatile than those of large cap companies. They may also be less liquid.


HEDGING: Any hedging strategy using derivatives may not achieve a perfect hedge.

Before subscribing, please refer to the Fund offering documents/prospectus for further risk factors and preinvestment disclosures. For the latest NAV, please visit www.bloomberg.com.

## **REGIONAL DISTRIBUTION (%)**







Totals may not add up to 100% due to rounding

#### **TOP 10 HOLDINGS**

Totals may not add up to 100% due to rounding

COMPANY NAME	COUNTRY	INDUSTRY	% OF EQUITY
Boston Scientific	United States	Medical Products	4.1
UnitedHealth Group	United States	Health Services	3.5
Anthem Inc	United States	Health Services	3.3
Bristol-Myers Squibb	United States	Major Pharmaceuticals	3.1
AstraZeneca PLC	United Kingdom	Major Pharmaceuticals	2.8
Thermo Fisher Scient	United States	Medical Products	2.6
Novartis AG	Switzerland	Major Pharmaceuticals	2.5
Eli Lilly & Co	United States	Major Pharmaceuticals	2.5
Allergan PLC	United States	Major Pharmaceuticals	2.4
Eisai Co Ltd	Japan	International Biotechnology	2.2
Total of Top 10			29.0
Number of Equity Names			129

#### Number of Equity Names

The individual issuers listed should not be considered a recommendation to buy or sell. The weightings do not reflect exposure gained through the use of derivatives. Holdings vary and there is no guarantee that the Fund will hold any of the securities listed. Please refer to the annual and semi-annual report for the full holdings.

In Canada, this material is provided by Wellington Management Canada ULC, a British Columbia unlimited liability company registered in the provinces of Alberta, British Columbia, Manitoba, Nova Scotia, New Brunswick, Newfoundland and Labrador, Ontario, Prince Edward Island, Quebec and Saskatchewan in the categories of Portfolio Manager and Exempt Market Dealer. UK:Wellington Management International Limited (WMIL), a firm authorised and regulated by the Financial Conduct Authority (FCA). Germany: Wellington Management International Limited, Niederlassung Deutschland, the German branch of WMIL, which is authorised and regulated by the Financial Conduct Authority (FCA). Germany: Wellington Management International Limited, Niederlassung Deutschland, the German branch of WMIL, which is authorised and regulated by the FCA and in respect of certain of its activities by the Bundesanstalt für Financientsteistungsaufsicht (BaFin). Shares of the Fund may not be distributed or marketed in any way to German retail or semi-professional investors if the Fund is not admitted for distribution to these investor categories by BaFin. Hong Kong: Prioritize function of the prior of the prio

## **SECTOR DISTRIBUTION (%)**